Loading data for EW — first visit, this takes a few seconds.

Alerta

Edwards Lifesciences Corp... (EW)

NYSE: EW · Precio en tiempo real · USD

92.28

+1.30 (1.43%)

Al cierre: Aug 19, 2026, 8:00 PM

91.00

-1.39%

Fuera de horario: 6:06 PM

1.43% (1D)

No hay datos disponibles

Precio de compra	92.26
Capitalización de mercado	53.19B
Ingresos (TTM)	6.51B
Beneficio neto (TTM)	979.9M
Beta	0.85
EPS (TTM)	1.68
Ratio PER (TTM)	54.93
Adelante PE	27.34
P/B (TTM)	5.01
P/S (TTM)	8.16
Earnings Date	Oct 29, 2026

Precio de venta	92.58
Volumen	2,316,034
Volumen medio (20D)	4,813,170
Abierto	91.47
Anterior Cerrar	90.98
Rango del día	91.27 - 93.25
Rango de 52 semanas	72.30 - 96.29
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de EW

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the ...

[Leer más]

Industria Medical Devices

Sector Healthcare

IPO Fecha Mar 27, 2000

Empleados 16,000

Bolsa de Valores NYSE

Símbolo bursátil EW

Sitio web https://www.edwards.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Edwards Lifesciences fueron 6.07B, un aumento de 11.55% en comparación con 5.44B del año anterior. Las ganancias fueron 1.07B, una disminución de -74.28%.

Estados financieros

Sorpresa de resultados

Edwards Lifesciences ha publicado sus resultados trimestrales en Jul 23, 2026:

Ingresos de n/a falla las estimaciones por $0, con -100.00% Disminución interanual.

EPS de 0.78 supera las estimaciones en 0.04, con 16.42% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Edwards Lifesciences Corporation publique sus resultados el Oct 29, 2026, después del cierre del mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

5 días hace · Zacks

Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?

Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.

6 días hace · Zacks

Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation

Edwards' 14% three-month rally reflects broad structural-heart growth, but its premium valuation raises the bar for execution.

1 semana hace · Barchart

Is Wall Street Bullish or Bearish on Edwards Lifesciences Stock?

Though Edwards Lifesciences has underperformed the broader market over the past year, Wall Street analysts maintain a strongly optimistic outlook on the stock’s prospects.

1 semana hace · Zacks

Can da Vinci 5 Drive Intuitive Surgical's Next Multi-Year Upgrade Cycle?

Intuitive Surgical's da Vinci 5 is gaining rapid adoption, fueling hospital upgrades as software enhancements build a potential multi-year capital cycle.

2 semanas hace · Insider Monkey

Edwards Lifesciences (EW) Has a Growth Runway Competitors May Struggle to Match

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% durin...

Página 1 de 2